Uttar Pradesh pharma investment is gaining strong momentum as the state moves ahead with a INR2,500 crore plan to build a robust healthcare manufacturing ecosystem.
.png)
Sun Pharmaceutical Industries Limited has rolled out its semaglutide injection in India under the brands Noveltreat and Sematrinity, widening access to treatments for type 2 diabetes and chronic weight management.
Indian Pharma Companies have kicked off an aggressive race in generic semaglutide after the patent for the blockbuster diabetes and weight-loss drug expired on March 20, 2026.
India's pharma sector evolves with Biopharma SHAKTI Scheme, focusing on biologics, biosimilars, and advanced therapies to boost global competitiveness and healthcare.
.png)
Natco Pharma has just shaken up the India’s diabetes drug market with its launch of semaglutide at just INR 1,290 a month, making high end diabetes treatment far more affordable for millions.
Bharat Biotech is advancing vaccines to fight drug resistance, focusing on preventing hospital infections and reducing antibiotic use as antimicrobial resistance grows into a major global health threat.
Zydus Lifesciences has partnered with Lupin to roll out its weight loss injection in India, expanding access to semaglutide in India for diabetes and obesity treatment as demand rises across the country.
.png)
Alkem Laboratories’ Baddi manufacturing facility in India receives Germany GMP certificate, validating compliance with international quality standards and boosting its global pharmaceutical presence.
Mankind Pharma is preparing to enter India’s fast-growing semaglutide market as the patent expiry opens doors for local drugmakers. The company plans an early launch to capture demand for diabetes and weight-loss treatments.
The Centre proposes reforms to simplify drug testing for plasma-derived medicines, eliminating redundant virus tests while ensuring high safety standards for patients.
.jpg)
.jpg)
, CDSCO.jpg)